What the human studies measured
The FDA review described two studies of night-shift workers using epitalon under the tongue and a separate study involving an inherited eye disease.
These were not studies of routine epitalon injections under the skin. FDA found no such human studies in its review.
That leaves a practical gap when a proposed treatment differs from the way a substance was tested. A result is not just the name of a substance followed by a benefit. It also has a setting, a group of people, a way the substance was given, and a question the researchers chose to ask.
For a sleep claim, the most direct question is whether sleep was measured. For a claim about living longer, ask whether the study followed people’s lives. A report about a different result may still be worth reading, but it answers a different question. Keep that gap visible rather than filling it with hope.
A sleep-related marker is not a sleep result
A night-work study described by FDA followed women for 20 days after tests found low levels of a substance in their urine. That substance is left after the body breaks down melatonin. The group receiving epitalon had a rise in that urine marker.
A marker is a measured clue, not the experience it might be linked to. Here, the study did not assess sleep outcomes or report safety data.
FDA also pointed to the study’s small size and short span. The published report did not say whether participants and researchers knew which spray each person received.
A placebo lets researchers compare the tested substance with a treatment that lacks it. Not knowing which group someone is in can help separate expectations from a treatment effect. Those study details help a reader judge what a result means. They cannot supply a sleep result that the researchers did not collect.
For a discussion about trouble sleeping, a useful request is: show the part of the paper that measures sleep. If the answer points only to urine testing, write down that exact limitation. There is no need to dismiss the entire paper to say that it does not settle your question.
Check the name before the headline
The older human reports about longer life used epithalamin, sometimes alongside another extract. They cannot show that epitalon extends human life.
Much of the published research on epitalon comes from a group of researchers in Russia and people who worked with them. The three human studies FDA described came from that same group.
This makes it useful to ask whether a result has been tested by another group and in the same setting as the proposed use. A new summary of an old result is not another test of it. Trace the summary back to the original study rather than counting how often the claim appears.
ClinicalTrials.gov is a U.S. government website that lists research studies. A search reviewed September 28, 2026 found no registered study under epitalon or epithalon that gave the substance to people to test its effects. The three human studies FDA found in published papers are a separate source of evidence. The published work still needs to be read.